Phosphodiesterase 5 Inhibitor [EPC]

This page covers all Phosphodiesterase 5 Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2, cGMP-specific 3',5'-cyclic phosphodiesterase, PDE5.

Targets

Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2 · cGMP-specific 3',5'-cyclic phosphodiesterase · PDE5

Marketed (3)

• Cialis · Eli Lilly · Urology
• Macitentan and Tadalafil · Humanis Saglık Anonim Sirketi
• Stendra · Vivus Llc · Hematology
  Stendra works by inhibiting an enzyme that breaks down a molecule called cyclic GMP, allowing blood vessels to relax and improve blood flow to the penis.

Phase 2 pipeline (1)

• Aristo Sildaristo · Aspargo Labs, Inc · Urology
  Aristo Sildaristo is a phosphodiesterase 5 inhibitor.

Patent intelligence

• phosphodiesterase 5 inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates